Latest Conference Coverage

AAIC Presentations Provide Context on Lecanemab’s Real-World Effect 2 Years Since Approval

A real-world study reveals lecanemab's effectiveness in early Alzheimer's, showing stability or improvement in 83.6% of patients after two years.

Alzheimer Vaccine ABvac40 Shows Potential to Slow Cognitive Decline in Phase 2 Study

Data presented at AAIC 2025 from a phase 2 study suggest that ABvac40 may slow cognitive decline in patients with Alzheimer disease, particularly among those who developed higher antibody levels.

Anti-Tau Agent Bepranemab Slows Tau Accumulation in Phase 2 TOGETHER Trial

UCB's bepranemab shows promise in slowing tau accumulation in early Alzheimer disease, marking an advancement in tau-targeted therapies.

Phase 3 Study Results of Obicetrapib on Alzheimer Disease Biomarker Progression: Philip Scheltens, MD, PhD

The Emeritus Professor of Cognitive Neurology at VU University Medical Center talked about findings presented at AAIC 2025 from the phase 3 BROADWAY trial of obicetrapib in Alzheimer disease. [WATCH TIME: 3 minutes]

Phase 2 PRIMUS-AD Trial to Test Anti-Amyloid Oligomer PRI-002 in Alzheimer Disease

A groundbreaking phase 2 study evaluates PRI-002's potential to treat mild Alzheimer's symptoms, aiming for significant safety and efficacy insights by 2026.

Valiltramiprosate Demonstrates Beneficial Imaging Impacts on Less Progressed Subgroup of APOE4 Homozygotes

Valiltramiprosate shows promising effects on brain structure and cognitive function in early Alzheimer disease, highlighting its potential for MCI treatment.

Findings From First Cohort of SPG302 in Phase 2 Alzheimer Disease Trial: Sharron Gargosky, PhD

The chief development officer at Spinogenix shared initial results from the first cohort of the company’s phase 2 trial assessing SPG302 in Alzheimer disease presented at AAIC 2025. [WATCH TIME: 6 minutes]

Eisai Showcases Promising 4-Year Data for Alzheimer Therapy Lecanemab at AAIC 2025

New data reveals lecanemab's long-term benefits for early Alzheimer's patients, showcasing improved cognitive outcomes and promising safety profiles over four years.

Enhancing Digital Cognitive Assessment for Mild Cognitive Impairment With Acoustic Metrics: Tanya Talkar, PhD

The senior data scientist at Linus Health discussed how acoustic and speech-based metrics can be used to capture subtle cognitive signals during neuropsychological assessments. [WATCH TIME: 6 minutes]

AAV2-BDNF Gene Therapy Restores FDG-PET Activity in Entorhinal Cortex, Phase 1 Data Show

AAV2-BDNF gene therapy shows promise in reversing cognitive decline in early Alzheimer's, enhancing neuronal function and safety in initial trials.

Streamlining Early Alzheimer Disease Detection With Remote Blood Biomarker Testing: Elisabeth Thijssen, PhD

The chief scientific officer at Neurogen Biomarking outlined a novel home-based diagnostic model that can accelerate detection of early AD through biomarker profiling. [WATCH TIME: 5 minutes]

NeuroVoices: Sylvia Villeneuve, PhD, on Detecting Preclinical Alzheimer Disease Through Blood Biomarkers and PET Imaging

The associate professor in the Department of Psychiatry at McGill University discussed the strengths and limitations of PET and blood biomarkers in identifying early Alzheimer disease.

Glutaminyl Inhibitor Varoglutamstat Fails to Show Efficacy in Phase 2 VIVA-MIND Study of Early Alzheimer Disease

Phase 2 VIVA-MIND study shows varoglutamstat is safe for early Alzheimer’s patients but fails to improve cognitive outcomes.

MRI Analysis Shows Brain Morphological Changes in Patients With Breast Cancer and Chemotherapy-Related Cognitive Impairment

A new analysis revealed structural brain differences among patients with breast cancer who experienced chemotherapy-associated cognitive impairment following anthracycline-taxane treatment.

Narcolepsy Treatment Trends and Change in Alerting Agent Use After Low-Sodium Oxybate Initiation

In this final episode, the sleep experts analyze real-world prescribing data to understand how low-sodium oxybate impacts the use of traditional alerting agents in narcolepsy. [WATCH TIME: 4 minutes]

Nicotinamide Riboside Shows Effects on Hippocampal Features but Not Improved Memory

New research reveals nicotinamide riboside supplementation enhances hippocampal perfusion in adults with mild cognitive impairment, but memory performance remains unchanged.

Debating on the Clinical Utility of Blood-Based Biomarkers for Alzheimer Diagnosis: Fanny Elahi, MD, PhD

The associate professor of neurology at Icahn School of Medicine at Mount Sinai discussed the clinical and scientific advantages of blood-based biomarkers over imaging for Alzheimer disease. [WATCH TIME: 5 minutes]

Using the Syn-One Test for Earlier Detection in Neurodegenerative Diseases: Todd Levine, MD

At AAIC 2025, the chief medical officer at CND Life Sciences discussed recent progress in detecting neurodegenerative diseases earlier using tools like the Syn-One Test. [WATCH TIME: 3 minutes]

Indirect Comparison Study Hints at Lower ARIA and ICH-Related Mortality Risk in Lecanemab Over Donanemab

Although the FDA-approved therapies lecanemab and donanemab both slow progression in early Alzheimer disease, a new study presented at AAIC 2025 highlighted differences in their safety profiles.

Structured Lifestyle Program Leads to Greater Cognitive Improvements in At-Risk Individuals Over Self-Guided Intervention

New research revealed that structured lifestyle programs could significantly enhance cognitive function in older adults at risk of decline, outperforming self-guided interventions.

Accelerometry Assessment of Factors Related to how TAK-861 Affects Disrupted Sleep in People with Narcolepsy Type 1

In episode 5, the sleep specialists examine actigraphy data from a study of TAK-861 in narcolepsy type 1 and discuss the promise of home-based sleep tracking in clinical care. [WATCH TIME: 3 minutes]

Physical Activity May Offset Cognitive Decline Risk in APOE ε4 Carriers, Study Finds

In a new study presented at AAIC 2025, findings showed that walking significantly slowed cognitive decline in APOE ε4 carriers, especially among Black and White women.

Combination Vascular Risk Therapies Tied to Slower Cognitive Decline, Less Dementia Pathology

A new study presented at AAIC 2025 suggested that combination therapy with cardiovascular medications was associated with slower cognitive decline in older adults.

Vibrance-3: Study Design and Methods for a Phase 2, Randomized, Placebo Controlled, Parallel-Group Study Evaluating the Safety and Efficacy of ALKS 2680 in Patients With Idiopathic Hypersomnia

In this segment, Eric Olson, MD, and Anita Shelgikar, MD, discuss the design of the Vibrance-3 trial, a phase 2 study of the orexin-2 receptor agonist ALKS 2680 in patients with idiopathic hypersomnia. [WATCH TIME: 4 minutes]

Social Determinants of Health and Clinical Burden in Narcolepsy: A Retrospective Cohort Analysis

In episode 3, Drs. Olson and Shelgikar break down a retrospective study exploring how social determinants of health impact the clinical experience of patients with narcolepsy. [WATCH TIME: 6 minutes]

Effectiveness and Safety of Low-Sodium Oxybate Dosages Greater Than 9 Grams in Study Participants With Narcolepsy

Panelists Eric Olson, MD, and Anita Shelgikar, MD, examine interim data on high-dose low-sodium oxybate in patients with narcolepsy, discussing safety signals, efficacy trends, and clinical considerations. [WATCH TIME: 4 minutes]

Connecting Patient-Reported Cognitive Symptoms With Objective Findings in Migraine: Laura Sebrow, PhD

The postdoctoral neuropsychology fellow at North Shore University Hospital talked about recognizing and aligning subjective cognitive complaints with objective assessments in patients with migraine during the interictal period. [WATCH TIME: 6 minutes]

Impact of Switching from High- to Low-Sodium Oxybate on Ambulatory Blood Pressure in Patients with Narcolepsy

In this episode, Eric Olson, MD, and Anita Shelgikar, MD, review the XYLO study’s findings on the impact of switching from high- to low-sodium oxybate on blood pressure in patients with narcolepsy.

NeuroVoices: Pam Conley and Alan Glicklich, MD, on NVG-2089’s Potential to Treat CIDP

Members from Nuvig Therapeutics discussed the rationale and therapeutic development of NVG-2089, a novel anti-inflammatory agent being studied for chronic inflammatory demyelinating polyneuropathy.

Exploring Use of AI Tools for Cardiovascular Risk Prediction in Migraine: Chia-Chun Chiang, MD

The associate professor of neurology at Mayo Clinic Rochester talked about using artificial intelligence-electrocardiogram at baseline to predict adverse vascular events in patients with migraine. [WATCH TIME: 5 minutes]